{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:13:40Z","timestamp":1784207620448,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.06.026","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:39:47Z","timestamp":1782715187000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug\/rifampicin-resistant tuberculosis in China: an open-label, multicentre, randomised controlled, noninferiority trial"],"prefix":"10.1016","author":[{"given":"Wen-wen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-dan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-guo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.06.026_bib1","unstructured":"Global tuberculosis report 2025. Geneva: World Health Organization, 2025. www.who.int\/publications\/i\/item\/9789240116924. Date accessed, November 2025"},{"key":"10.1016\/j.cmi.2026.06.026_bib2","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. https:\/\/www.who.int\/publications\/i\/item\/9789241550529. Date accessed, July 2019"},{"key":"10.1016\/j.cmi.2026.06.026_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.06.026_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib5","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMc2009939","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Nimmo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.06.026_bib8","series-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment \u2013 Drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.cmi.2026.06.026_bib9","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 4: Treatment\u2014drug-resistant tuberculosis treatment, 2022 update. World Health Organization; 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240063129. Date accessed: January 5, 2025"},{"key":"10.1016\/j.cmi.2026.06.026_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijid.2018.10.026","article-title":"Relationship between chest radiographic characteristics, sputum bacterial load, and treatment outcomes in patients with extensively drug-resistant tuberculosis","volume":"79","author":"Te Riele","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.026_bib11","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1038\/s41467-024-53273-7","article-title":"AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis","volume":"15","author":"Chang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.06.026_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/s41591-025-03742-3","article-title":"Strategies for shortening tuberculosis therapy","volume":"31","author":"Dartois","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib13","doi-asserted-by":"crossref","first-page":"731.e9","DOI":"10.1016\/j.cmi.2021.09.014","article-title":"Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China","volume":"28","author":"Liu","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.06.026_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s12879-022-07482-4","article-title":"Prediction of drug resistance profile of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) isolates from the newly diagnosed case by whole genome sequencing (WGS): A study from a high tuberculosis burden country","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.026_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02155-18","article-title":"In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.06.026_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00131-9","article-title":"The catalog of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: A genomic analysis","volume":"5","author":"Pei","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2026.06.026_bib17","first-page":"733","article-title":"Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment","volume":"42","year":"2019","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.cmi.2026.06.026_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.06.026_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2026.06.026_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jinf.2023.03.020","article-title":"Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas","volume":"86","author":"Wang","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2026.06.026_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172549","article-title":"Impairment of Wnt\/\u03b2-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis","volume":"12","author":"Fan","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cmi.2026.06.026_bib22","unstructured":"Office for Policy in Clinical Research Operations, National Institutes of Health. DAIDS adverse event grading tables. 2017 (https:\/\/rsc.tech-res.com\/clinical-research-sites\/safety-reporting\/daids-grading-tables). Date accessed: 2017"},{"key":"10.1016\/j.cmi.2026.06.026_bib23","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","article-title":"Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavorable interim microbiological treatment outcome: An observational study","volume":"24","author":"Singh","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.06.026_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14787210.2024.2303032","article-title":"Drug recommendation for optimization on treatment outcome for MDR\/RR-TB based on a multi-center, large-scale, retrospective cohort study in China","volume":"22","author":"Fan","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2026.06.026_bib26","first-page":"137","article-title":"The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data","volume":"17","author":"Shanshan","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.cmi.2026.06.026_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/cid\/ciz915","article-title":"Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: A randomized control trial in China","volume":"71","author":"Yadong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.026_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: Analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.06.026_bib29","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib30","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/cid\/ciaf527","article-title":"Xpert MTB\/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification","volume":"82","author":"Grint","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.06.026_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): An open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2026.06.026_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S2213-2600(25)00080-3","article-title":"Equitable, personalised medicine for tuberculosis: Treating patients, not diseases","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:23:37Z","timestamp":1784204617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S1198743X26003393"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.06.026","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug\/rifampicin-resistant tuberculosis in China: an open-label, multicentre, randomised controlled, noninferiority trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}